Shenzhen Hepalink Pharmac... (SHEZF)
Shenzhen Hepalink Pharmaceutical Statistics
Share Statistics
Shenzhen Hepalink Pharmaceutical has 3.48B shares outstanding. The number of shares has increased by -7.19% in one year.
| Shares Outstanding | 3.48B |
| Shares Change (YoY) | -7.19% |
| Shares Change (QoQ) | -6.66% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.23B |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 2K, so 0% of the outstanding shares have been sold short.
| Short Interest | 2K |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 999.99 |
Valuation Ratios
The PE ratio is 7.78 and the forward PE ratio is null. Shenzhen Hepalink Pharmaceutical's PEG ratio is -0.04.
| PE Ratio | 7.78 |
| Forward PE | n/a |
| PS Ratio | 0.95 |
| Forward PS | n/a |
| PB Ratio | 0.41 |
| P/FCF Ratio | 2.53 |
| PEG Ratio | -0.04 |
Enterprise Valuation
Shenzhen Hepalink Pharmaceutical has an Enterprise Value (EV) of 6.32B.
| EV / Sales | 1.2 |
| EV / EBITDA | 5.27 |
| EV / EBIT | 2.88 |
| EV / FCF | 3.17 |
Financial Position
The company has a current ratio of 2.6, with a Debt / Equity ratio of 0.25.
| Current Ratio | 2.6 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 2.48 |
| Debt / FCF | 1.5 |
| Interest Coverage | 5.25 |
Financial Efficiency
Return on Equity is 5.32% and Return on Invested Capital is 4.12%.
| Return on Equity | 5.32% |
| Return on Assets | 3.73% |
| Return on Invested Capital | 4.12% |
| Revenue Per Employee | $2.74M |
| Profits Per Employee | $335.8K |
| Employee Count | 1,926 |
| Asset Turnover | 0.3 |
| Inventory Turnover | 0.65 |
Taxes
| Income Tax | 101.31M |
| Effective Tax Rate | 13.95% |
Stock Price Statistics
The stock price has increased by -34.78% in the last 52 weeks. The beta is 0.46, so Shenzhen Hepalink Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.46 |
| 52-Week Price Change | -34.78% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.49 |
| Relative Strength Index (RSI) | 0 |
| Average Volume (20 Days) | 5 |
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical had revenue of 5.28B and earned 646.74M in profits. Earnings per share was 0.44.
| Revenue | 5.28B |
| Gross Profit | 1.76B |
| Operating Income | 741.31M |
| Net Income | 646.74M |
| EBITDA | 1.2B |
| EBIT | 867.41M |
| Earnings Per Share (EPS) | 0.44 |
Balance Sheet
The company has 1.69B in cash and 2.98B in debt, giving a net cash position of -1.29B.
| Cash & Cash Equivalents | 1.69B |
| Total Debt | 2.98B |
| Net Cash | -1.29B |
| Retained Earnings | 4.03B |
| Total Assets | 17.55B |
| Working Capital | 6B |
Cash Flow
In the last 12 months, operating cash flow was 2.19B and capital expenditures -202.77M, giving a free cash flow of 1.99B.
| Operating Cash Flow | 2.19B |
| Capital Expenditures | -202.77M |
| Free Cash Flow | 1.99B |
| FCF Per Share | 1.36 |
Margins
Gross margin is 33.26%, with operating and profit margins of 14.04% and 12.25%.
| Gross Margin | 33.26% |
| Operating Margin | 14.04% |
| Pretax Margin | 13.75% |
| Profit Margin | 12.25% |
| EBITDA Margin | 22.7% |
| EBIT Margin | 14.04% |
| FCF Margin | 37.71% |
Dividends & Yields
SHEZF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 12.86% |
| FCF Yield | 39.6% |
Analyst Forecast
Currently there are no analyst rating for SHEZF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 1.38 |
| Piotroski F-Score | 6 |